Group A Streptococcus ‘needle-free’ vaccine trials to begin, a Griffith University and Olymvax partnership

Researchers with Griffith University in Australia and the Chinese pharmaceutical firm, Olymvax announced that they will begin Phase 1 clinical trials on a new, needle-free vaccine targeted at Streptococcus A infection, the cause of strep throat and rheumatic heart disease. Griffith University signed the collaborative and license agreement with Olymvax to discover, develop and commercialize its Group A ["]